Thomas Cappola
Overview
Explore the profile of Thomas Cappola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flam E, Jang C, Murashige D, Yang Y, Morley M, Jung S, et al.
Nat Cardiovasc Res
. 2023 Feb;
1(9):817-829.
PMID: 36776621
Heart failure (HF) is a leading cause of mortality. Failing hearts undergo profound metabolic changes, but a comprehensive evaluation in humans is lacking. We integrate plasma and cardiac tissue metabolomics...
2.
Puckelwartz M, Pesce L, Dellefave-Castillo L, Wheeler M, Pottinger T, Robinson A, et al.
J Am Heart Assoc
. 2021 Mar;
10(7):e019944.
PMID: 33764162
Background Inherited cardiomyopathies display variable penetrance and expression, and a component of phenotypic variation is genetically determined. To evaluate the genetic contribution to this variable expression, we compared protein coding...
3.
Chirinos J, Cohen J, Zhao L, Hanff T, Sweitzer N, Fang J, et al.
Hypertension
. 2020 Sep;
76(5):1526-1536.
PMID: 32981365
ACE2 (angiotensin-converting enzyme 2) is a key component of the renin-angiotensin-aldosterone system. Yet, little is known about the clinical and biologic correlates of circulating ACE2 levels in humans. We assessed...
4.
Cohen J, Schrauben S, Zhao L, Basso M, Cvijic M, Li Z, et al.
JACC Heart Fail
. 2020 Jan;
8(3):172-184.
PMID: 31926856
Objectives: This study sought to assess if clinical phenogroups differ in comprehensive biomarker profiles, cardiac and arterial structure/function, and responses to spironolactone therapy. Background: Previous studies identified distinct subgroups (phenogroups)...
5.
Celik S, Karbalaei Sadegh M, Morley M, Roselli C, Ellinor P, Cappola T, et al.
JCI Insight
. 2019 Sep;
4(19).
PMID: 31503546
The cardiac hormone atrial natriuretic peptide (ANP) is a central regulator of blood volume and a therapeutic target in hypertension and heart failure. Enhanced ANP activity in such conditions through...
6.
Cordero P, Parikh V, Chin E, Erbilgin A, Gloudemans M, Shang C, et al.
Nat Commun
. 2019 Jun;
10(1):2760.
PMID: 31235787
Heart failure is a leading cause of mortality, yet our understanding of the genetic interactions underlying this disease remains incomplete. Here, we harvest 1352 healthy and failing human hearts directly...
7.
Dubin R, Deo R, Bansal N, Anderson A, Yang P, Go A, et al.
Clin J Am Soc Nephrol
. 2017 Jan;
12(1):60-68.
PMID: 28062676
Background And Objectives: Heart failure is the most frequent cardiac complication of CKD. Left ventricular hypertrophy is common and develops early in CKD, but studies have not adequately evaluated the...
8.
Keenan T, Zhao W, Rasheed A, Ho W, Malik R, Felix J, et al.
J Am Coll Cardiol
. 2016 Jan;
67(4):407-416.
PMID: 26821629
Background: Although epidemiological studies have reported positive associations between circulating urate levels and cardiometabolic diseases, causality remains uncertain. Objectives: Through a Mendelian randomization approach, we assessed whether serum urate levels...
9.
Perez M, Pavlovic A, Shang C, Wheeler M, Miller C, Liu J, et al.
J Am Coll Cardiol
. 2015 Dec;
66(22):2522-33.
PMID: 26653627
Background: The genetic determinants of heart failure (HF) and response to medical therapy remain unknown. We hypothesized that identifying genetic variants of HF that associate with response to medical therapy...
10.
Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer N, et al.
Circulation
. 2015 Mar;
131(6):e344.
PMID: 25815393
No abstract available.